MDACC Study No:2010-0451 ( NCT No: NCT01413191)
Title:Phase II Study of IMC-A12 in Metastatic Uveal Melanoma
Principal Investigator:Sapna P. Patel
Treatment Agent:IMC-A12
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if IMC-A12 (cixutumumab)
can help control metastatic uveal melanoma. Researchers will study how
cixutumumab affects the levels of tumor markers, chemicals in the blood and
tissue related to the growth and spread of cancer cells. Researchers will
study the effects of the study drug, good and/or bad, on the insulin-like
growth factor-1 receptor (IGF-1R), a natural protein in the body that may be
related to metastatic uveal melanoma. The safety of cixutumumab will also be
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase II
Treatment Agents:IMC-A12
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Imclone
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sapna P. Patel
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults